Acadia Pharmaceuticals Inc. (ACAD) Stock Price

ACADStock

$29.11+10.98%52W

Market Cap$5.02B

P/E12.51x

PEG Ratio50.86

Div yield—

Beta0.86

ACAD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)6.45%

Price vs S&P 500 (4W)12.12%

PEG Ratio50.86

VGM Score60.07

P/E Ratio (Annual)12.51x

P/CF (Annual)44.52x

Book Value / Share (Quarterly)$7.59

P/TBV (Annual)4.04x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.83%

Cash Flow / Share (Quarterly)$0.85

Price vs S&P 500 (YTD)-3.84%

Gross Margin (TTM)91.13%

Net Profit Margin (TTM)33.42%

EPS (TTM)$2.21

10-Day Avg Trading Volume1.46M

EPS Excl Extra (TTM)$2.21

Revenue Growth (5Y)15.68%

EPS (Annual)$2.30

ROI (Annual)31.86%

Gross Margin (Annual)91.69%

Net Profit Margin (5Y Avg)-4.95%

Cash / Share (Quarterly)$5.56

P/E Basic Excl Extra (TTM)12.85x

Revenue Growth QoQ (YoY)16.40%

P/E Normalized (Annual)12.51x

ROA (Last FY)25.00%

Revenue Growth TTM (YoY)47.00%

EBITD / Share (TTM)$0.51

ROE (5Y Avg)3.38%

Operating Margin (TTM)7.59%

Cash Flow / Share (Annual)$0.04

P/B Ratio3.74x

P/B Ratio (Quarterly)3.32x

Net Income / Employee (Annual)$491,200

EV / Revenue (TTM)3.96x

Net Interest Coverage (TTM)-30.69x

ROA (TTM)24.38%

EPS Growth QoQ (YoY)15.24%

EV / EBITDA (TTM)51.49x

EPS Incl Extra (Annual)$2.30

Current Ratio (Annual)3.83x

Quick Ratio (Quarterly)3.11x

3-Month Avg Trading Volume1.62M

52-Week Price Return10.98%

EV / Free Cash Flow (Annual)714.18x

P/E Incl Extra (TTM)12.85x

Revenue / Employee (TTM)$1,430,500

Tangible BV / Share (Quarterly)$6.99

P/S Ratio (Annual)4.56x

Asset Turnover (Annual)0.69x

52-Week High$30.96

Operating Margin (5Y Avg)-10.93%

EPS Excl Extra (Annual)$2.30

Tangible BV CAGR (5Y)9.93%

26-Week Price Return18.38%

Quick Ratio (Annual)3.49x

13-Week Price Return34.58%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.39x

Enterprise Value$4.51B

Revenue / Share Growth (5Y)14.54%

Asset Turnover (TTM)0.73x

Book Value / Share Growth (5Y)23.88%

Revenue / Employee (Annual)$1,346,100

Inventory Turnover (Annual)3.14x

Pretax Margin (Annual)12.96%

Cash / Share (Annual)$4.81

3-Month Return Std Dev35.41%

Gross Margin (5Y Avg)94.35%

Net Income / Employee (TTM)$478,000

ROE (Last FY)31.86%

Net Interest Coverage (Annual)-30.69x

EPS Basic Excl Extra (Annual)$2.30

P/FCF (TTM)24.65x

Receivables Turnover (TTM)8.82x

EV / Free Cash Flow (TTM)30.94x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$2.21

Receivables Turnover (Annual)9.73x

ROI (TTM)32.39%

P/S Ratio (TTM)4.29x

Pretax Margin (5Y Avg)-8.60%

Revenue / Share (Annual)$6.31

Tangible BV / Share (Annual)$6.57

Forward P/E41.36x

Price vs S&P 500 (52W)-7.58%

P/E Ratio (TTM)12.85x

EPS Growth TTM (YoY)96.46%

Year-to-Date Return8.99%

5-Day Price Return-1.82%

EPS Normalized (Annual)$2.30

ROA (5Y Avg)0.90%

Net Profit Margin (Annual)36.49%

Month-to-Date Return12.52%

Cash Flow / Share (TTM)$-0.88

EBITD / Share (Annual)$0.62

Operating Margin (Annual)9.78%

LT Debt / Equity (Annual)0.01x

P/CF (TTM)30.50x

ROI (5Y Avg)3.38%

P/E Excl Extra (TTM)12.85x

LT Debt / Equity (Quarterly)0.03x

EPS Basic Excl Extra (TTM)$2.21

P/TBV (Quarterly)3.60x

P/B Ratio (Annual)3.68x

Inventory Turnover (TTM)3.45x

Pretax Margin (TTM)10.66%

Book Value / Share (Annual)$7.21

Price vs S&P 500 (13W)32.63%

Beta0.86x

P/FCF (Annual)775.21x

Revenue / Share (TTM)$6.59

ROE (TTM)32.39%

52-Week Low$19.69

vGradeC

gGradeB

mGradeB

vgmGradeB

ACAD Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 4, 2026	$0.04	$0.18	+317.25%(+$0.14)
Q1 2026	May 6, 2026	$0.08	$0.02	-75.22%(-$0.06)
Q4 2025	Feb 25, 2026	$0.14	$0.14	-4.19%(-$0.01)
Q3 2025	Nov 5, 2025	$0.15	$0.42	+189.02%(+$0.27)
Q2 2025	Aug 6, 2025	$0.14	$0.16	+15.27%(+$0.02)

ACAD Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ACADAcadia Pharmaceuticals Inc.	C	B	B	$29.11
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biopharmaceutical company with two core franchises in neurological and rare diseases. Its neurological franchise is anchored by NUPLAZID (pimavanserin), the first FDA-approved treatment for Parkinson's disease psychosis, while its rare disease franchise is built on DAYBUE, the first FDA-approved treatment for Rett syndrome. The company's clinical pipeline includes programs targeting Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and other neurological disorders.